Board of Directors

Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and is the current Chair of the OBN UK Ltd. He has over 40 years’ experience in the pharmaceutical and life science field; he has worked for Beecham Pharmaceuticals & Genzyme Corporation, where he headed the UK operations. In 2000, he became CEO of UK based biosimilars’ organisation, GeneMedix (GMX) plc and successfully led a dual listing on the London and Singapore Stock Exchanges. Paul has acted as a NED to Goldshield Group plc & BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups. He acted as interim CEO to NanoMab Technology Ltd with an exit to Radiopharm Theranostics. He has served as Managing Partner and board member of the global Executive Search Group, Horton International since 2011.

In a biopharma career spanning over twenty-five years, Dr. Lundemose brings extensive international experience in areas of management, business development, corporate development, M&A strategy, and execution, financing as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity and anti-infectives. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. He is currently Chairman of the Board at Commit Biologics.

Dr. Lundemose has been CEO of Mission Therapeutics since 2015 and was CEO of publicly listed Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, which was subsequently reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, Dr. Lundemose held several senior management roles, most latterly as Executive Vice President Corporate Development & Strategy Officer, OSI, New York. Notably he was responsible for the acquisition of the DP-IV patent estate from Probiodrug generating 30 times return on investment. He was also involved in the sale of OSI Pharmaceuticals to Astellas Pharma for $4 billion.

Dr. Lundemose has been involved in a total of six biotech exits/IPOs and has held Board positions on over 12 Biotech Companies.

Dr. Lundemose is a qualified medical doctor and has a D.M.Sc and a Ph.D from the University of Aarhus, Denmark.

As a translational researcher for the last 32 years and Professor at Universities of Bristol, Nottingham and Pretoria, Prof Bates has spun out three companies based on his discoveries, and as Founding Director of the University of Nottingham Centre for Cancer Sciences from 2017 to 2023 has run strategic initiatives that cross multiple disciplines. David co-founded Exonate Ltd (2013), a Cambridge based clinical stage company developing anti-angiogenic eye drops where he was the Chief Scientific Officer until 2022. He has acted as a scientific advisor to major pharmaceutical companies including Pfizer, Takeda and Alcon. His academic research has contributed to the development of therapeutics in vascular eye disease and in cancer through collaborations with Roche and Astra Zeneca. He has published more than 200 papers and is the inventor on 13 patents.

ShiYin Foo is the scientific founder and CEO of Arvada Therapeutics. She is a cardiologist and immunologist with over 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has been in executive roles at multiple biotechnology companies, including Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics and Cydan II, and is currently on the Board of Directors at Thryv Therapeutics. ShiYin received her MD and PhD in Immunology from Stanford University, and a MMSc in Clinical Science from the Clinical Investigator Training Program at Harvard Medical School. She was clinical faculty at the Massachusetts General Hospital and Harvard Medical School, and a dual Diplomate of the American Board of Internal Medicine and in Cardiology.

Tom Needham, MBA, is Head of the Biopharmaceuticals practice at Broadview Ventures where he manages the firm’s biotechnology investment strategy and activity, from identification and screening of new opportunities, through due diligence, deal structure and syndication, portfolio company board management and overarching portfolio strategy.

Tom is also the Managing Director of Longview Ventures, an independent investment vehicle focused on clinical-stage opportunities, as a complement to Broadview’s dedication to Seed and Series A financings.

Tom has over 30 years of experience in venture capital investing, business development, corporate strategy, and C-suite executive management responsibilities in public and private biotechnology companies. Tom currently serves on the boards of IsomAb and Basking Biosciences, including serving as Basking’s Chairman (2020 thru 2023). He also serves as board observer at Comanche Bio, HAYA Therapeutics, Alveron Pharma and Mosanna Therapeutics. Previously, Tom represented Broadview on the board at Antag Therapeutics, Renovacor (NYSE: RCOR, acquired by Rocket Pharma), including serving as Renovacor’s Chairman (2019 thru 2021), and held board observer roles at NIDO Surgical (acquired) and Cardero Therapeutics (now Epirium Bio).  Tom’s prior venture investment experience also includes working on Astex Pharmaceuticals (NASDAQ: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (NASDAQ: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and Aegerion Pharmaceuticals (NASDAQ: AEGR).

Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (NASDAQ: MACK) and Senior Vice President, Business Development at C4 Therapeutics (NASDAQ: CCCC). Prior to that, Tom spent 13 years as a healthcare and life sciences venture capital investor as Managing Director at Synthesis Capital and as a Principal at the global private equity firm Advent International, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, where he led the negotiation and closing of a number of strategic transactions, including R&D partnerships with global pharmaceutical companies, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.

Hannah Tapsell Chapman is an investor at Mercia Ventures, one of the UK’s most active venture capital firms. Hannah joined Mercia Ventures in September 2022 and focuses on high-growth business in the Midlands. Bringing with her over a decade of experience working with early-stage companies, Hannah’s role includes the origination, evaluation and negotiation of new deals as well as portfolio company board involvement. Hannah currently serves on the boards of various Mercia Ventures portfolio businesses, including NuVision, IsomAb, 6 Bit Education and ImmuONE. Prior to joining Mercia Ventures, Hannah worked in the venture building team at the Ministry of Defence, advising founders on commercialising their innovations and raising investment. She started her career at the London Stock Exchange Group where she spent seven years working across Capital Markets. Hannah holds a BSc from the University of Nottingham.

Laura is a Principal at SCVC, the official VC arm of Science Creates, where she invests in early-stage deep tech companies. She serves as Investor Director on the board of SCVC portfolio companies including Isomab and Bitrobius Genetics. Laura has broad experience across the life sciences. She is a Biochemist with seven years research experience across industry and university settings, holding Masters and Doctoral degrees in Biochemistry from the University of Oxford. Her research experience includes three years at TCR T-cell therapy biotech Adaptimmune. Prior to joining SCVC in 2021, Laura worked at BBSRC-UKRI developing funding programmes to support the commercialisation of academic research.